Donanemab is an investigational antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.
All articles by Brian Park, PharmD
This case report described the first instance of a patient with Crohn disease and relapsing polychondritis who presented with pachymeningitis.
Publish Date
This first-in-class, serotonin (5-HT) 1F receptor agonist is believed to exert its therapeutic effects both centrally and peripherally.
Publish Date
Mylan Pharmaceuticals announced the voluntary recall of one lot of alprazolam 0.5mg tablets to the consumer/user level due to the potential presence of a foreign substance.
Publish Date
-
Latest News Your top articles for Friday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses